Dihydrocodeine Schedule II and III

{
  "description" : "This value set includes semantic clinical drugs (SCD) and generic pack (GPCK) RxNorm codes.",
  "compose" : {
    "exclude" : [ ],
    "include" : [ {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "extension" : [ {
        "extension" : [ {
          "valueString" : "concept",
          "url" : "path"
        }, {
          "url" : "count",
          "valueInteger" : 3
        } ],
        "url" : "http://health-samurai.io/extensions/excised-data"
      } ]
    } ]
  },
  "date" : "2021-02-23T01:01:00-05:00",
  "meta" : {
    "versionId" : "10",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ]
  },
  "publisher" : "Lantana EH Steward",
  "jurisdiction" : [ {
    "coding" : [ {
      "system" : "urn:iso:std:iso:3166",
      "code" : "US"
    } ]
  } ],
  "purpose" : "(Clinical Focus: The purpose of this value set is to group Schedules II and III Dihydrocodeine medications.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that identify medications of dihydrocodeine),(Exclusion Criteria: Excludes concepts that represent schedule I, V,  unscheduled, nonprescribable, non-human, and inactive Dihydrocodeine medications.)",
  "name" : "DihydrocodeineScheduleIIAndIII",
  "experimental" : false,
  "resourceType" : "ValueSet",
  "expansion" : {
    "contains" : [ {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1596108",
      "display" : "acetaminophen 320.5 MG / caffeine 30 MG / dihydrocodeine bitartrate 16 MG Oral Capsule",
      "version" : "04012024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1812164",
      "display" : "acetaminophen 325 MG / caffeine 30 MG / dihydrocodeine bitartrate 16 MG Oral Tablet",
      "version" : "04012024"
    } ],
    "total" : 2,
    "identifier" : "urn:uuid:61199c97-cfea-4360-be95-d1e1aa489f82",
    "timestamp" : "2024-04-23T08:48:24-04:00"
  },
  "title" : "Dihydrocodeine Schedule II and III",
  "extension" : [ {
    "valueString" : "Lantana EH Author",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author"
  }, {
    "valueDate" : "2023-02-28",
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate"
  }, {
    "valueDate" : "2021-02-23",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate"
  }, {
    "url" : "http://health-samurai.io/extensions/source",
    "valueCode" : "db"
  } ],
  "status" : "active",
  "id" : "d37836bf-d624-4b2c-a6df-0a5a128c8fd4",
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.170",
  "identifier" : [ {
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113762.1.4.1111.170"
  } ],
  "version" : "20210223"
}